SCHEMBL2273019

SCHEMBL2273019

CN(CC=O)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4195366 0.84 PHF8 (0.33)
SCHEMBL867322 0.78
SCHEMBL14029230 0.76
SCHEMBL4252185 0.76
SCHEMBL20221160 0.76
SCHEMBL14398391 0.75
SCHEMBL14397786 0.75 PHF8 (0.37)
SCHEMBL14397983 0.75 PHF8 (0.52)
SCHEMBL25398910 0.74
SCHEMBL2332433 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001066534-A2 CYCLIC AND BICYCLIC DIAMINO HISTAMINE-3 RECEPTOR ANTAGONISTS ABBOTT LABORATORIES (US) 2001-09-13 WO claimed
EP-3883926-B1 BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS REGENERON PHARMA (US) 2024-07-10 EP disclosed
WO-2023152349-A1 IRAK4 INHIBITORS ASTRAZENECA AB (SE) 2023-08-17 WO disclosed
WO-2023086438-A1 PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF EMORY UNIVERSITY (US) 2023-05-19 WO disclosed
US-20220363677-A1 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER VERNALIS (R&D) LTD (GB) 2022-11-17 US disclosed
WO-2022123530-A1 BORONIC ACID COMPOUND 주식회사 엘지화학 2022-06-16 WO disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 EP disclosed
EP-3883926-A1 BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS Regeneron Pharmaceuticals, Inc. (US) 2021-09-29 EP disclosed
EP-3856192-A1 DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF Dana Farber Cancer Institute, Inc. (US) 2021-08-04 EP disclosed
WO-2021127480-A1 SYNTHETIC TRITERPENOIDS WITH NITROGEN-BASED SUBSTITUENTS AT C-17 AND METHODS OF USE THEREOF REATA PHARMACEUTICALS, INC. (US) 2021-06-24 WO disclosed
US-5610157-A N-(3-hydroxy-4-piperidinyl) (dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzo-dioxin) carboxamide derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1997-03-11 US disclosed
US-5576448-A GASTROINTESTINAL DISORDERS, ANTIEMETICS, ANTIPSYCHOTICS OR NEUROLEPTIC AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1996-11-19 US disclosed
US-5565582-A GASTROINTESTINAL DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 1996-10-15 US disclosed
US-5554772-A CHEMICAL INTERMEDIATES; GASTROINTESTINAL DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 1996-09-10 US disclosed
US-5552553-A CHEMICAL INTERMEDIATES FOR LAXATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1996-09-03 US disclosed
US-5536733-A GASTROINTESTINAL JANSSEN PHARMACEUTICA N.V. (BE) 1996-07-16 US disclosed
US-5521314-A CHEMICAL INTERMEDIATES FOR CENTRAL NERVOUS SYSTEM, ANTIEMETICS, ANTIPSYCHOTIC AGENTS OR NEUROLEPTIC AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1996-05-28 US disclosed
EP-0389037-B1 N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-09-20 EP disclosed
US-5374637-A Stimulate gastrointestinal motility JANSSEN PHARMACEUTICA N.V. (BE) 1994-12-20 US disclosed
EP-0389037-A1 N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-09-26 EP disclosed